Phil Rotella

[Phil Rotella @RotellaPhil]

@MattNachtrab @JoeCanepa2 Based on what we’ve seen from the current MABs data, it doesn’t appear that plaque stripping is of any help and actually detrimental to brain health. The key is hitting the causative factor upstream which is what Simufilam is doing.

[Matt Nachtrab @MattNachtrab]

Chemiotics II, retired practicing neurologist, wrote an article highlighting the significance of $Sava simufilam having zero drug related side effects including no Aria in MRI scans. He correctly claims this along with clinical efficacy will result in FDA approval after phase 3 completes. Monoclonal Antibody treatments have about 30% occurrence of brain bleeds.

With simufilam, it’s important to note that the good AB42 increased in a one month trial by 15% with p<.0015. In Alzheimer’s, the soluble AB42 decreases as AB aggregates in plaques. Therefore, it shows benefits in AB but does not have the side effects. Additionally, the clinical benefits outpace the MAB treatments.

The reason the MAB treatments are not being prescribed by honest doctors is the cost, logistics, benefit, and health risk do not make logical sense to prescribe.

If I had a male friend that was diagnosed with Alzheimer’s that was NOT Apoe4, I would consider recommending it, but that is only about 20% of people that get AD.

A greedy doctor may recommend it all day long because it’s very profitable. Is this why the @alzassociation pushes MABs but ignores the large phase 3 of simufilam?

It makes you wonder why Jordan Thomas, David Bredt and other short sellers wanted to stop such a promising drug? They literally asked the FDA to stop a proven safe drug. Maybe the zero-success Bredt wanted to beat Lindsay and Hoau to an AD treatment? Is the ambitious drug development industry so competitive they are willing to slow down small vulnerable researchers? Do they understand the suffering this causes to families worldwide?

So many unanswered questions that I pray the DOJ tries to answer after they see what I already know. They have perused the wrong suspect and the drug works.

https://t.co/j8FTKRuHRU

[Phil Rotella @RotellaPhil]

@MattNachtrab Obvious he’s a pay to play dude. In bed with the ChiComms and anyone else with a buck. Disgusting state of affairs this administration is in. Our Founding Fathers rolling in their graves..

[Matt Nachtrab @MattNachtrab]

Once the detractors of $sava start capitulating and suggesting simufilam is likely get FDA approval, others will follow. Lane engaged in years of discussions and now sees that the FDA is likely to approve simufilam for treatment of mild AD. This is a big deal and thank you Lane!

https://t.co/TyyM63UJnX

[Phil Rotella @RotellaPhil]

@BillE78059 If SAVA already has the patent on Simufilam isn't this infringement?

[Bill England @BillE78059]

$SAVA Those following the saga of $SAVA for years have to be scratching their heads. For those who haven't, let me provide you with a little bit of history. When $SAVA released it P2A trial data of Simufilam in early 2021, it was remarkably better than anything that had ever been seen for the treatment of Alzheimer's disease. The stock price skyrocketed to over $130. Then, Dr. David Bredt, et. al. filed a citizen's petition with the FDA asking them to stop P3 trials of Simufilam and conduct an investigation into the basic research conducted by Dr. Wang, claiming the western blots in his research papers were altered and therefor maybe fraudulent. Within 24 hours, articles were published not in science or medical journals, but in financial journals. If you looked on the Yahoo articles list for $SAVA, you couldn't find any because of dozens of lawyers advertising for clients to join into class action lawsuits against $SAVA. It was obvious that this was a planned and well-coordinated short and distort campaign against $SAVA. And by the way, Bredt somehow forgot to disclose to the FDA that he held a large short position in $SAVA.

You will regularly see bashing posts by Adrian H. and EndAlzFraud, as well as critical articles by Lane Simonian, Adam Feuerstein and more recently, Charles Piller. Adrian and Bredt are named defendants in a defamation lawsuit filed by $SAVA.

Fast forward, Bredt founded a company, Rapport Therapeutics, aimed at developing therapeutic drugs for treating AD. Why I mentioned those who have followed the $SAVA saga for years might be scratching their heads is because there's been a bizarre event lately. Rapport recently added a new BOD member, the former CEO of Alnylam. Alnylam filed an application of a patent, citing the work of Drs. Wang and Burns as a cornerstone of the related science. Smell fishy or just coincidence?
https://t.co/tFNk0shqyt

[ChrisRock002 @ChrisRock002]

$SAVA Reminder that Simufilam was peer reviewed FOUR times &amp; Ph.3 study Rethink will end in only 7 Months!
Cochin Institute (Paris) "Publication of new research that confirms the biological activity of Simufilam using TR-FRET", International Journal of Molecular Sciences #ENDALZ

[Lara Williamson @willia94981]

One step back: Why the new Alzheimer's plaque-attack drugs don't work https://t.co/Frxr5AdQRo Unlike the existing AD drugs on the market that target plaques, $SAVA has a novel approach to treating Alzheimer's that focuses on treating misfolded proteins. #CassavaSciences #ENDALZ

[Historical Sample @SJ79716665]

Simufilam the first truly disease modifying therapy for AD (and eventually for a broad array of faulty FLNA-related conditions) -- medical history unfolding. Dawning realization of the novel from the unknown/unexpected takes time. Appreciate what we hold in this little community

[Historical Sample @SJ79716665]

What if you read this in mainstream media -- No decline in Cognition Scores in Patients with Mild AD who were treated w/Simu continuously for 24mths. Imagine being a family in need or an investor unaware. The day is approaching when more than just us few will know.

[Phil Rotella @RotellaPhil]

@SJ79716665 Can't come soon enough. Phase 2 CMS scores and greenlight from DSMB should be enough for BTD.

[Matt Nachtrab @MattNachtrab]

Again this is a great chart from someone that has done a great job deeply researching and seeing through the corruption of short sellers of $sava. Thanks @TruthfulHand for all your work for #Alzheimers victims.

[Matt Nachtrab @MattNachtrab]

Great reminder of how professional the $sava board is. The shorts are dead wrong about $sava. The former No. 2 at the FBI with 24k federal agents reporting to him does not join a board of a company after ACCUSED of being a fraud if the accusations have any credibility.

[Phil Rotella @RotellaPhil]

@TruthfulHand @CassavaSciences Possible they've submitted data to FDA per SPA agreement and are seeking AA or BTD?

[Phil Rotella @RotellaPhil]

I'm in the running to Win a FOLIOT Scubanaut Dive Watch with a value of $799 / £628 / €735! Help to #retweet &amp; #share https://t.co/Blj7xawzDb @foliotwatches #foliot #scubadiving #competition #sweepstakes

[Phil Rotella @RotellaPhil]

@Archisaurus_YMB @Jebs_Twit Strong counter by EC and the team!

[Bill England @BillE78059]

Does Simufilam from $SAVA work? An associate just reported that he has a friend who finished the Refocus clinical trial in Sept. His starting MMSE was 17. His ending MMSE was 24. He is continuing in the P3 OL. Anyone who says anecdotal information doesn't matter is lying.

[Phil Rotella @RotellaPhil]

@BrianWilsonLive #brianwilsonsgrabbag The young ones already loving the Beach Boys! Merry Christmas from our family to your and yours @BrianWilsonLive!

[Phil Rotella @RotellaPhil]

@Artixera @MattNachtrab She's an obvious bought and paid for hack for her Patreon donors..

[Phil Rotella @RotellaPhil]

@mikeaglover1 Odds on he's a butt hurt, bitter liberal egged on by his gun, and freedom hating friends.